Minerva Neurosciences, Inc. Earnings Per Share (Diluted)
Minerva Neurosciences, Inc. (NERV) reported Earnings Per Share (Diluted) of -$0.14 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-07
- Minerva Neurosciences, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.14.
- Minerva Neurosciences, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$2.86.
- Minerva Neurosciences, Inc. earnings per share, diluted for the quarter ending 2025-12-31 was -$25.45.
- Minerva Neurosciences, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was -$0.36, a 112.12% decline year-over-year.
- Minerva Neurosciences, Inc. earnings per share, diluted for fiscal 2025 was -$34.67, a 18347.37% decline from fiscal 2024.
- Minerva Neurosciences, Inc. earnings per share, diluted for fiscal 2024 was $0.19.
- Minerva Neurosciences, Inc. earnings per share, diluted for fiscal 2023 was -$4.61.
- Minerva Neurosciences, Inc. earnings per share, diluted for fiscal 2022 was -$6.01.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 3 month as first filed | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 9 month as first filed | Earnings Per Share, Diluted 12 month | Earnings Per Share, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.14 10-Q · filed 2026-08-07 | -$2.38 10-Q · filed 2026-08-07 | -$8.76 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$11.13 derived: net income ÷ weighted average shares · filed 2026-08-07 | |||
| 2026-03-31 | -$2.86 10-Q · filed 2026-05-05 | -$14.86 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$19.73 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$23.66 derived: net income ÷ weighted average shares · filed 2026-08-07 | |||
| 2025-12-31 | -$25.45 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$30.61 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$33.06 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$34.67 10-K · filed 2026-03-11 | |||
| 2025-09-30 | -$0.36 10-Q · filed 2025-11-05 | -$0.79 derived: net income ÷ weighted average shares · filed 2026-08-07 | -$1.29 10-Q · filed 2025-11-05 | -$1.85 derived: net income ÷ weighted average shares · filed 2026-08-07 | |||
| 2025-06-30 | -$0.43 10-Q · filed 2026-08-07 | -$0.93 10-Q · filed 2026-08-07 | -$1.49 derived: net income ÷ weighted average shares · filed 2026-08-07 | $1.48 derived: net income ÷ weighted average shares · filed 2026-08-07 | |||
| 2025-03-31 | -$0.50 10-Q · filed 2026-05-05 | -$1.06 derived: net income ÷ weighted average shares · filed 2026-08-07 | $1.91 derived: net income ÷ weighted average shares · filed 2026-08-07 | $0.83 derived: net income ÷ weighted average shares · filed 2026-08-07 | |||
| 2024-12-31 | -$0.57 derived: net income ÷ weighted average shares · filed 2026-04-23 | $2.41 derived: net income ÷ weighted average shares · filed 2026-04-23 | $1.32 derived: net income ÷ weighted average shares · filed 2026-04-23 | $0.19 10-K · filed 2026-03-11 | |||
| 2024-09-30 | $2.97 10-Q · filed 2025-11-05 | $1.89 derived: net income ÷ weighted average shares · filed 2025-11-05 | $0.75 10-Q · filed 2025-11-05 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-04-23 | |||
| 2024-06-30 | -$1.09 10-Q · filed 2025-08-14 | -$2.22 10-Q · filed 2025-08-14 | -$3.41 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$4.44 derived: net income ÷ weighted average shares · filed 2026-04-23 | |||
| 2024-03-31 | -$1.13 10-Q · filed 2025-05-13 | -$2.32 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$3.36 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$4.48 derived: net income ÷ weighted average shares · filed 2026-04-23 | |||
| 2023-12-31 | -$1.19 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$2.22 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$3.34 derived: net income ÷ weighted average shares · filed 2026-04-23 | -$4.61 10-K · filed 2025-02-25 | |||
| 2023-09-30 | -$1.03 10-Q · filed 2024-11-05 | -$2.14 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$3.41 10-Q · filed 2024-11-05 | -$4.66 derived: net income ÷ weighted average shares · filed 2024-11-05 | |||
| 2023-06-30 | -$1.12 10-Q · filed 2024-08-06 | -$2.43 10-Q · filed 2024-08-06 | -$3.68 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$4.98 derived: net income ÷ weighted average shares · filed 2024-11-05 | |||
| 2023-03-31 | -$1.31 10-Q · filed 2024-05-01 | -$2.56 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$3.86 derived: net income ÷ weighted average shares · filed 2024-11-05 | -$5.49 derived: net income ÷ weighted average shares · filed 2024-11-05 | |||
| 2022-12-31 | -$1.26 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$2.55 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$4.18 derived: net income ÷ weighted average shares · filed 2024-02-22 | -$6.01 10-K · filed 2024-02-22 | |||
| 2022-09-30 | -$1.29 10-Q · filed 2023-11-07 | -$2.92 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$4.75 10-Q · filed 2023-11-07 | -$8.74 derived: net income ÷ weighted average shares · filed 2023-11-07 | |||
| 2022-06-30 | -$1.63 10-Q · filed 2023-08-01 | -$3.46 10-Q · filed 2023-08-01 | -$7.45 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$9.17 derived: net income ÷ weighted average shares · filed 2023-11-07 | |||
| 2022-03-31 | -$1.83 10-Q · filed 2023-05-15 | -$5.82 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$7.54 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$3.46 derived: net income ÷ weighted average shares · filed 2023-11-07 | |||
| 2021-12-31 | -$3.99 derived: net income ÷ weighted average shares · filed 2023-03-08 | -$5.71 derived: net income ÷ weighted average shares · filed 2023-03-08 | -$2.31 derived: net income ÷ weighted average shares · filed 2023-03-08 | -$9.35 10-K · filed 2023-03-08 | -$1.17 10-K · filed 2022-03-01 | ||
| 2021-09-30 | -$1.72 10-Q · filed 2022-11-09 | -$0.22 10-Q · filed 2021-11-08 | -$0.82 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$5.36 10-Q · filed 2022-11-09 | -$0.67 10-Q · filed 2021-11-08 | ||
| 2021-06-30 | -$0.25 10-Q · filed 2021-08-02 | -$0.45 10-Q · filed 2021-08-02 | |||||
| 2020-12-31 | -$0.17 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$0.37 derived: net income ÷ weighted average shares · filed 2022-03-01 | $0.34 derived: net income ÷ weighted average shares · filed 2022-03-01 | $0.05 10-K · filed 2022-03-01 | |||
| 2020-09-30 | -$0.19 10-Q · filed 2021-11-08 | $0.52 derived: net income ÷ weighted average shares · filed 2021-11-08 | $0.23 10-Q · filed 2021-11-08 | ||||
| 2020-06-30 | $0.73 10-Q · filed 2021-08-02 | $0.43 10-Q · filed 2021-08-02 | |||||
| 2019-12-31 | -$0.77 derived: net income ÷ weighted average shares · filed 2021-03-08 | -$1.12 derived: net income ÷ weighted average shares · filed 2021-03-08 | -$1.44 derived: net income ÷ weighted average shares · filed 2021-03-08 | -$1.85 10-K · filed 2021-03-08 | |||
| 2019-09-30 | -$0.36 10-Q · filed 2020-11-02 | -$0.68 derived: net income ÷ weighted average shares · filed 2021-03-08 | -$1.08 10-Q · filed 2020-11-02 | ||||
| 2019-06-30 | -$0.32 10-Q · filed 2020-08-03 | -$0.73 10-Q · filed 2020-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |